deltatrials
Completed PHASE1 NCT00937404

Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants

An Open-label Primary Vaccination Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Three-dose Primary Vaccination Course at 2, 3 and 4 Months of Age in Healthy Infants in China.

Sponsor: GlaxoSmithKline

Conditions Poliomyelitis
Interventions Poliorix
Updated 8 times since 2017 Last updated: May 31, 2018 Started: Aug 4, 2009 Primary completion: Nov 13, 2009 Completion: Nov 13, 2009

This PHASE1 trial investigates Poliomyelitis and is currently completed. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2009 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2019 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2019 [monthly]

    Completed PHASE1

▶ Show 3 earlier versions

  1. Jun 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Feb 2017 — Jun 2017 [monthly]

    Completed PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Wuzhou, China